Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moschel

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Cancer Research|July 1, 1994
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecanH S Friedman, M E Dolan, S H Kaufmann, et al.
Molecular Cancer Therapeutics|September 16, 2004
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutationsManny D Bacolod, Stewart P Johnson, Anthony E Pegg, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicityMelissa L Fishel, David R Newell, Roger J Griffin, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
Geniom technology--the benchtop array facilityR Güimil, M Beier, M Scheffler, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferaseH S Friedman, A E Pegg, S P Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant gliomaH S Friedman, D M Kokkinakis, J Pluda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Nucleic Acids Research|November 25, 2003
Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profilingMichael Baum, Simone Bielau, Nicole Rittner, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Cancer Research|July 1, 1994
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecanH S Friedman, M E Dolan, S H Kaufmann, et al.
Molecular Cancer Therapeutics|September 16, 2004
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutationsManny D Bacolod, Stewart P Johnson, Anthony E Pegg, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicityMelissa L Fishel, David R Newell, Roger J Griffin, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 21, 2003
Geniom technology--the benchtop array facilityR Güimil, M Beier, M Scheffler, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferaseH S Friedman, A E Pegg, S P Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant gliomaH S Friedman, D M Kokkinakis, J Pluda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Nucleic Acids Research|November 25, 2003
Validation of a novel, fully integrated and flexible microarray benchtop facility for gene expression profilingMichael Baum, Simone Bielau, Nicole Rittner, et al.
Pageof 11